Analysts’ Weekly Ratings Updates for AnaptysBio (ANAB)

AnaptysBio (NASDAQ: ANAB) recently received a number of ratings updates from brokerages and research firms:

• 12/19/2024 – AnaptysBio had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an “overweight” rating on the stock.
• 12/18/2024 – AnaptysBio had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a “hold” rating on the stock.
• 12/12/2024 – AnaptysBio had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an “overweight” rating on the stock.
• 12/12/2024 – AnaptysBio had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a “buy” rating on the stock.
• 12/11/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $40.00 price target on the stock, down previously from $42.00.
• 12/11/2024 – AnaptysBio was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $19.00 price target on the stock, down previously from $52.00.
• 12/2/2024 – AnaptysBio was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
• 11/14/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
• 11/12/2024 – AnaptysBio had its price target lowered by analysts at JPMorgan Chase & Co. from $75.00 to $66.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – AnaptysBio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
• 11/6/2024 – AnaptysBio had its price target lowered by analysts at HC Wainwright from $55.00 to $52.00. They now have a “buy” rating on the stock.
• 10/31/2024 – AnaptysBio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
• 10/30/2024 – AnaptysBio had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a “neutral” rating on the stock.

AnaptysBio Stock Down 4.1 %

Shares of AnaptysBio stock traded down $0.56 on Friday, reaching $13.18. The company’s stock had a trading volume of 128,918 shares, compared to its average volume of 388,409. The company has a market capitalization of $401.05 million, a price-to-earnings ratio of -2.17 and a beta of -0.11. The firm’s fifty day simple moving average is $22.22 and its two-hundred day simple moving average is $28.87. AnaptysBio, Inc. has a 52 week low of $13.18 and a 52 week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. As a group, research analysts predict that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Institutional Trading of AnaptysBio

Several hedge funds have recently modified their holdings of ANAB. Values First Advisors Inc. acquired a new position in AnaptysBio in the 3rd quarter worth approximately $49,000. nVerses Capital LLC boosted its stake in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the last quarter. Headlands Technologies LLC boosted its position in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd grew its stake in shares of AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 5,342 shares during the period.

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.